Mitogen Activated Protein Kinase 8 Market Dynamics, News, Key Developments

Posted by Deeksha on October 1st, 2019

Market Research Hub (MRH) has actively uploaded a smart research report titled “Mitogen Activated Protein Kinase 8-Pipeline Review, H2 2019”, to its broad online database. The primary motive of this study is to impart vital details associated to development of the Mitogen Activated Protein Kinase 8. The assessment includes brief knowledge about market size, Y-o-Y growth, market dynamics and competitive scenario expected to transform in the near future. Ever section of the report contains imperative market data that can prove useful for new entrants and industry players to draw crucial tactics.

Request Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519495

Mitogen Activated Protein Kinase 8 - Pipeline Review, H2 2019

Summary

Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Mitogen Activated Protein Kinase 8 - Pipeline Review, H2 2019, outlays comprehensive information on the Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Mitogen-activated protein kinase 8 is an enzyme encoded by the MAPK8 gene. It is involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. It phosphorylates the replication licensing factor CDT1, inhibiting the interaction between CDT1 and the histone H4 acetylase HBO1 to replication origins. Loss of this interaction abrogates the acetylation required for replication initiation. It promotes stressed cell apoptosis by phosphorylating key regulatory factors including p53/TP53 and Yes-associates protein YAP1. It mediates starvation-induced BCL2 phosphorylation, BCL2 dissociation from BECN1, and thus activation of autophagy.

The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Ear Nose Throat Disorders, Gastrointestinal, Genito Urinary System And Sex Hormones, Oncology, Ophthalmology and Respiratory which include indications Parkinson's Disease, Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Sensorineural Hearing Loss, Alzheimer's Disease, Breast Cancer, Idiopathic Pulmonary Fibrosis, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Non-Alcoholic Steatohepatitis (NASH), Ocular Inflammation, Ocular Pain (Eye Pain) and Post-Operative Pain.

Furthermore, this report also reviews key players involved in Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Browse Complete Research Report with TOC@ https://www.marketresearchhub.com/report/mitogen-activated-protein-kinase-8-pipeline-review-h2-2019-report.html

Scope

- The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24)
- The report reviews Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope